![]() |
A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and… |
![]() |
New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1 It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1 These patients tend to… |
![]() |
In The News: TNF-Alpha Inhibitors Receive More Warnings...
October 1, 2011 - In the News / Politics By Ebey P. Soman – TNF-alpha inhibitors are drugs used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, as well as other disease states. These agents suppress the immune system and increase the risk of developing serious infections. Currently, there are five approved drugs in this category: • Adalimumab (Humira®, Abbott) • Certolizumab pegol… |